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Dendritic cells (DCs) are sentinels of the immune system
and represent a heterogeneous cell population. The exis-
tence of distinct DC subsets is due to their inherent
plasticity and to the changing microenvironment modulat-
ing their immunological properties. Numerous signalling
pathways have impacts on DCs. It appears that besides
cytokines/chemokines, lipid mediators also have profound
effects on the immunogenicity of DCs. Some of these lipid
mediators exert an effect through nuclear hormone recep-
tors. Interestingly, more recent ﬁndings suggest that DCs
are able to convert precursors to active hormones, ligands
for nuclear receptors. Some of these DC-derived lipids, in
particular retinoic acid (RA), have a central function in
shaping T-cell development and effector functions. In this
review, we summarize and highlight the function of a set
of nuclear receptors (PPARc, RA receptor, vitamin D
receptor and glucocorticoid receptor) in DC biology.
Deﬁning the contribution of nuclear hormone receptor
signalling in DCs can help one to understand the regula-
tory logic of lipid signalling and allow the exploitation of
their potential for therapeutic intervention in various
immunological diseases.
The EMBO Journal (2008) 27, 2353–2362. doi:10.1038/
emboj.2008.160; Published online 21 August 2008
Subject Categories: signal transduction; immunology
Keywords: dendritic cells; immunity; lipid signalling; nuclear
receptors; PPARg
Immunological functions of dendritic cells
serve the regulation of the adaptive
immune response
Antigen presentation is a key step in engaging the adaptive
immune response. Traditionally, macrophages and B cells
were thought to be the only cell types able to present antigens
to T cells and thus elicit immune response. The pioneering
work of Steinman and Cohn showed that a third kind of
antigen-presenting cell types, dendritic cells (DCs), are indis-
pensable for the initiation of the adaptive immune response
(Steinman and Cohn, 1973; Banchereau and Steinman,
1998). The migratory, tissue-resident DCs work at the inter-
face of peripheral tissues and lymphoid organs. These cells
are sentinels of the immune system, and they sense and
translate environmental cues by sampling and processing
extracellular and intracellular antigens (Figure 1). DCs are
able to pick up antigens using various uptake mechanisms
(Norbury, 2006; Savina and Amigorena, 2007). A key deﬁning
feature of this cell type is that after antigen uptake and
processing, DCs migrate to lymph nodes, where they present
antigens and stimulate T cells (Figure 1, insert). DCs are
armed with numerous receptors that detect ‘danger’ signals
in the surrounding environment. These signals, associated
with an ongoing infection, such as pathogen-associated mo-
lecular patterns or pro-inﬂammatory cytokines, cause DCs to
undergo phenotypic changes (maturation, activation) that
maximize their ability to elicit proliferation of T cells.
Mature DCs have an extraordinary capacity to activate
naive T cells owing to the high expression of various co-
stimulatory molecules (Ni and O’Neill, 1997). However, be-
sides eliciting immune response, DCs could also provoke
immunological tolerance by inducing deletion or anergy;
thus, DCs contribute to limiting autoimmunity (Cools et al,
2007). There are several mechanisms for the maintenance of
peripheral tolerance, one of which is when external stimuli
reprogramme DCs towards a less activated tolerogenic
cell type.
DCs form a heterogeneous cell population, which could be
classiﬁed as plasmacytoid or conventional DCs (Shortman
and Naik, 2007). DCs could also be subdivided into migratory
DCs, which reside in peripheral tissues, or lymphoid organ-
resident DCs, which constitute 50% of the lymph node DCs,
and all the splenic and thymic DCs (Villadangos and
Schnorrer, 2007). The molecular details of the regulation of
DC differentiation are still poorly characterized, although it
was described and suggested that several cytokines and
transcription factors are necessary for DC development
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2353(Zenke and Hieronymus, 2006; Wu and Liu, 2007). Flt3
ligand is critical for the development of both conventional
and plasmacytoid DC differentiation; in contrast, GM-CSF
promotes only conventional DC development (Wu and Liu,
2007). In addition, in humans, treatment with IL-4 and GM-
CSF cytokine is used for the ex vivo generation of monocyte-
derived DCs (Sallusto and Lanzavecchia, 1994). Much less is
known about the transcriptional regulation of DC develop-
ment, and only a few putative ‘master’ transcription factors
have been identiﬁed so far (Zenke and Hieronymus, 2006).
A microarray study indicated that some nuclear proteins/
transcription factors, including PPARg and LXRa nuclear
hormone receptors, are induced during monocyte-derived
DC development (Le Naour et al, 2001). Our global gene
expression proﬁling also showed that 20 out of 48 nuclear
receptors are present in human monocyte-derived DCs
(L Nagy et al, unpublished results). These ﬁndings indicate
that nuclear receptors are likely to have functions in the
differentiation and function of this cell type.
Nuclear hormone receptors are ligand-activated transcrip-
tion factors that modulate gene expression through binding to
speciﬁc hormone response elements. It is well established
that ligands/hormones (i.e. retinoids (metabolites of vitamin A),
vitamin D, glucocorticoids (GCs)) of nuclear receptors,
besides regulating development and metabolism, also have
an impact on the immune system. It was assumed that the
main immune targets of these ligands are lymphocytes. Now
this picture is being altered by ﬁndings that activators of
these receptors can also modulate DC differentiation and
function. In the ﬁrst part of this review, we will provide an
introduction to the function of lipids in DC biology, and
then summarize the potential function of nuclear hormone
receptors in DC differentiation and function. We will focus on
RXR heterodimeric receptors (PPAR, RAR, LXR and vitamin D
receptor (VDR)) and also discuss the potential function of GC
receptors in DC function. In the second part, we will provide
an overview on how endogenous ligand production for these
receptors is taking place in DCs.
DCs are exposed to lipids
In the body, there are several tissue compartments in which
DCs are likely to be exposed to large amounts of lipids. An
obvious one is the gut-associated lymphoid tissue (GALT)
where diet-derived lipids, fatty acids, retinoids and cholesterol
are abundant (Figure 1). In the small intestine, the lamina
propria is important to maintain peripheral tolerance towards
commensal bacterial ﬂora (Nagler-Anderson and Shi, 2001),
and the dietary lipid mediators might contribute to this type
of tolerance. It is well established that the atherosclerotic
plaques contain macrophages and Tcells; however, DCs were
also detected in the plaques (Bobryshev and Lord, 1995;
Angeli et al, 2004). In this microenvironment, cells are
encountering oxidized low-density lipoproteins (oxLDL). In
addition, several other active lipid mediators might be pre-
sent, which could modulate the migratory and immunologi-
cal properties of the cells (Figure 1).
Tissue-resident DCs sense and translate environmental
cues by sampling and processing protein antigens; however,
these cells can also present lipid/glycolipid antigens through
CD1 cell surface molecules (Brigl and Brenner, 2004). CD1s
molecules are critical for the presentation of various bacterial
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Figure 1 The immunological function of DCs. Differentiation and migration of tissue-resident DCs. DC precursors are bone marrow-derived
cells that leave the blood vessel and reside in various tissues in the periphery (for example, epidermis, intestine or the vessel wall or the
atherogenic plaque) as immature DCs. These cells are well armed for sampling antigens and can receive various cues from the surrounding
tissues. Antigen uptake associated with ‘danger signals’ leads to DC maturation and migration of draining lymph nodes. In the lymph nodes,
mature DCs present antigens to naive T cells and activate them.
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ways in which endogenous lipids are recognized and pre-
sented are still poorly characterized (Tsuji, 2006). An inter-
esting aspect of lipid antigen presentation is that extracellular
lipid particles facilitate the uptake of pathogen-derived CD1
ligands. For example, apoptotic bodies from mycobacterium-
infected macrophages are efﬁcient vehicles for lipid uptake of
uninfected DCs (Schaible et al, 2003); in addition, a CD1d
ligand precursor is delivered to DCs by apolipoproteins (van
den Elzen et al, 2005). These results underscore the notion
that the local lipid environment has the ability to modify the
lipid presentation capacity of DCs. In addition, lipid-derived
mediators also elicit intracellular signalling, which alters the
maturation and immunogenicity of the antigen-presenting
cells. Human monocyte-derived DC maturation is induced
by oxLDL exposure and this effect is mediated by lysoph-
osphatidyl choline through the activation of a G-protein-
coupled receptor (Coutant et al, 2002). DCs also sense and
integrate lipid signals through PG receptors; for example, DC
migration and cytokine production could be modulated by
PGE2 and LTB4. PGD is also an important modulator of DC
function (Harizi and Gualde, 2005). As we have brieﬂy high-
lighted, DCs sense the lipid environment by various cell
membrane receptors, and now there is an increasing amount
of evidence to suggest that DCs could also survey the lipid
environment by lipid sensing nuclear hormone receptors. In
the following section, we summarize the potential function of
these lipid-activated nuclear receptors in DCs.
The function of lipid-activated nuclear
hormone receptors PPARs and LXRs in DCs
Candidates for sensing the lipid environment in DCs are the
PPAR receptors. PPARs are fatty acid sensors that regulate
various facets of lipid metabolism. There are three isotypes of
PPARs, a, g and d/b. These receptors have key physiological
functions; for example, PPARa promotes fatty acid oxidation
in the liver (Lefebvre et al, 2006), PPARg is indispensable for
adipocyte differentiation and generally stimulates lipid
storage (Willson et al, 2001), and PPARd is an important
regulator of skeletal muscle lipid oxidation (Barish et al,
2006). Recent ﬁndings indicated that these receptors, espe-
cially PPARg, have important functions in DC biology
(Figure 2). Initially, a comprehensive microarray study in-
dicated that in humans, monocyte-derived DCs have an
elevated expression of PPARg (Le Naour et al, 2001). This
ﬁnding was consistent with a previous observation indicating
that IL-4 is a positive regulator of PPARg in human and
murine monocytes/macrophages (Huang et al, 1999). Later,
it was conﬁrmed by several laboratories that both the mRNA
and also the protein of PPARg are induced in human mono-
cyte-derived DCs (Gosset et al, 2001; Nencioni et al, 2002;
Szatmari et al, 2004). In addition, we found that the bona ﬁde
PPARg target (FABP4/aP2) is highly upregulated upon PPARg
ligand treatment in developing human DCs. Moreover, ex vivo
cultured blood-derived conventional (CD1cþ) DCs also ex-
press PPARg. Finally, in human lymphoid tissues (tonsils),
several PPARg and S100 double-positive cells were detected,
suggesting that at least a sub-population of lymphoid tissue
DCs express this receptor (Szatmari et al, 2004). Murine
splenic CD11cþ DCs also express PPARg (Faveeuw et al,
2000) and this nuclear receptor was detected in bone mar-
row-derived murine DCs (Hammad et al, 2004). The changes
in PPARg expression during various stages of DC develop-
ment are still poorly characterized; however, it was described
that the CD1a-negative population of monocyte-derived DCs
express more PPARg than the CD1a-positive counterparts
(Gogolak et al, 2007).
The effects of PPARg activators on the immunological
function and phenotype of ex vivo cultured DCs were inves-
tigated in detail. PPARg-activated immature DCs have an
enhanced phagocytic activity; in addition, these cells possess
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Figure 2 Effects of nuclear receptor agonists on the immunophenotype of DCs. Characteristic changes of cell surface markers and cytokine
production on DCs on nuclear receptor activation. Here, we summarize the effects of PPARg activators, retinoids, glucocorticoids and the active
form of vitamin D on monocyte-derived DCs.
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et al, 2004; Appel et al, 2005). PPARg-activated human DCs
produce less IL-12 and TNFa; moreover, these cells secrete
lower amounts of MCP2, IP-10 and RANTES chemokines
(Gosset et al, 2001; Nencioni et al, 2002) (Figure 2).
Furthermore, PPARg-instructed DCs have an altered cell sur-
face expression pattern of co-stimulatory molecules; they
express less CD80 but increased CD86 (Gosset et al, 2001;
Nencioni et al, 2002; Szatmari et al, 2004). These observa-
tions appeared to be consistent with a model in which PPARg-
activated DCs skew the differentiation to a special DC subset
that has a reduced Th1 activation capacity but an enhanced
Th2 activation propensity (Faveeuw et al, 2000; Gosset et al,
2001). Others suggested that the activation of the PPARg
pathway generally reduces/inhibits the immunogenicity of
developing human DCs (Nencioni et al, 2002; Appel et al,
2005). Recently, in murine DCs, a similar effect was observed,
suggesting that PPARg activation has a negative effect on the
stimulatory capacity of DCs. More importantly, in the same
report, PPARg-deﬁcient DCs were used and the authors found
that PPARg’s effects on the stimulatory capacity of the cells
are receptor dependent (Klotz et al, 2007). However, the
molecular mechanism of this negative regulation is not
clear. By analogy, the anti-inﬂammatory properties of
PPARg ligands are better characterized in murine macro-
phages. One suggested mechanism for this activity is the
sumoylation of the receptor and recruitment of co-repressors
on the promoter region of NF-kB-binding sites of various
inﬂammatory genes (Pascual et al, 2005). In DCs, it was
suggested that the PPARg ligand treatment interfered with the
activation of the NF-kB and the MAP kinase pathways (Appel
et al, 2005). Interestingly, besides these essentially inhibitory
activities, PPARg appears to possess positive regulatory activ-
ities in immune cells as well. Our recent global gene expres-
sion proﬁling study revealed that on acute PPARg ligand
treatment, more than 100 genes were immediately induced
and most of these early activated genes fall into the lipid
metabolism category (Szatmari et al, 2007). In contrast,
immune response-related genes were induced only after
24h or later, suggesting that PPARg activation directly reg-
ulates lipid metabolism of these cells but rather indirectly
modiﬁes the immune phenotype of DCs. As we have de-
scribed in the previous section, DCs are able to present lipid
antigens by CD1 antigen-presenting molecules. Our results
indicated that the PPARg ligand coordinately regulates the
CD1 gene family expression in human monocyte-derived
DCs. PPARg-activated DCs express less CD1a (Nencioni
et al, 2002; Szatmari et al, 2004), but have an elevated
expression of CD1d. More importantly, the elevated expres-
sion of CD1d was coupled to the enhanced capacity to
activate a CD1d-dependent cell type, the iNKT (invariant
natural killer T) cells (Szatmari et al, 2004). The lack of
iNKT cell activation has been implicated in the development
of autoimmune conditions, suggesting that iNKT cells are
intimately linked to sustaining immunological tolerance
(Hammond and Kronenberg, 2003). We also deﬁned the
possible mechanism for this regulation: PPARg indirectly
stimulated the expression of CD1d through the production
of all-trans retinoic acid (ATRA), the natural ligand of RA
receptors (RARs) (Szatmari et al, 2006a). Conﬁrming this, it
was reported recently that the human CD1d promoter con-
tains a retinoid response element (Chen and Ross, 2007). We
also described that PPARg-activated DCs have an elevated
expression of ABCG2, a xenobiotic transporter. These results
suggested that the PPARg activation modiﬁes the xenobiotic
and drug resistance of human DCs (Szatmari et al, 2006b).
The functions of the other two PPAR receptors are poorly
characterized in DCs. We and others described that DCs
express very low levels of PPARa. Consistent with this
ﬁnding, PPARa ligand treatment has only a marginal effect
on monocyte-derived DC differentiation and function (Gosset
et al, 2001; Szatmari et al, 2004). In contrast, it was shown
that PPARa is present in human epidermal DCs (Langerhans
cells) and that the activation of the PPARa pathway blocks
the activation and migration of these skin DCs (Dubrac et al,
2007). Curiously, DCs also express PPARd (Szatmari et al,
2004), but the potential role of these receptors in DC function
is not yet characterized. Another metabolite receptor, the
liver X receptors (LXRs), the sensor of oxidized forms of
cholesterol (Zelcer and Tontonoz, 2006), were reported to be
upregulated during monocyte-derived DC development;
moreover, LXR ligand-treated DCs have a reduced T-cell
activation capacity (Geyeregger et al, 2007). These nuclear
hormone receptors are metabolic sensors. The natural ligands
of these receptors are poorly characterized (polyunsatured
fatty acids, oxidized fatty acids or cholesterol). Therefore,
much remains to be discovered how the receptor’s endogen-
ous activation takes place. Nevertheless, high-afﬁnity syn-
thetic ligands for these receptors are available to probe their
function in DCs ex vivo and potentially in vivo. In the next
sections, we describe the potential function of two receptors
having a high-afﬁnity hormonal ligand in DC biology.
Vitamin D and GCs are modulators of DC
differentiation and activation
Activators of GC and VDRs have profound immunosuppres-
sive effects. It was assumed that lymphocytes are the main
target of these compounds. However, several in vitro and
some in vivo observations suggested that GCs and vitamin D
also diminished the immunogenicity of DCs and that these
effects might contribute to the impaired immune response
and to the anti-inﬂammatory effects. There are a few recent
reviews that provide an overview on the immunosuppressive
effects of GCs and vitamin D on DCs (Abe and Thomson,
2003; Hackstein and Thomson, 2004; van Etten and Mathieu,
2005), and thus we only brieﬂy discuss the effects of these
ligands on DC biology.
The immunosuppressive effects of GCs have been well
documented and several studies have suggested that, among
other cell types, DCs are also affected. GCs decrease the co-
stimulatory molecule expression in murine DCs, and there-
fore these cells have a poor T-cell stimulatory capacity in vitro
and in vivo (Moser et al, 1995). In humans, GC-treated
monocyte-derived DCs have a reduced T-cell activation capa-
city; moreover, GCs interfere with the differentiation of DCs
from monocytes (Piemonti et al, 1999; Rea et al, 2000)
(Figure 2). The anti-inﬂammatory effects of GCs are well
characterized, but the molecular mechanisms are still poorly
deﬁned (Hackstein and Thomson, 2004). It has been shown
that GCs regulate the immune function of T cells and DCs
parallelly by the coordinated activation of the GITR ligand in
T cells and the induction of GITR receptors in plasmacytoid
DCs. This signalling in DCs leads to a non-canonical
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(IDO), a key enzyme that catalyses the initial and rate-limit-
ing step in the degradation of tryptophan and a negative
modulator of lymphocyte proliferation (Grohmann et al,
2007). In addition, GCs exert an IDO-dependent protection
in a model of allergic airway inﬂammation. These observa-
tions clearly establish DCs as valid targets of GC action.
The active form of vitamin D also has immunosuppressive
effects, and numerous studies have shown that the regulation
of DC immunofunctions is an important part of this profound
suppressive activity. 1a,25 dihydroxy vitamin D3 highly
suppresses the activation/maturation of DCs; moreover,
these cells have diminished T-cell activation capacity
(Penna and Adorini, 2000; Piemonti et al, 2000) (Figure 2).
An in vivo murine model has also conﬁrmed that the admin-
istration of VDR agonist negatively modulates the stimulatory
capacity of DCs. Consistent with this ﬁnding, VDR-deﬁcient
mice have hypertrophy of subcutaneous lymph nodes and an
elevated number of mature DCs (Grifﬁn et al, 2001). The
ways in which VDR carries out its functions, whether it
interferes with positive signalling or induces suppressor
molecules directly or simply inhibits DC differentiation
and/or maturation is not clear. It was suggested that VDR
transcriptionally represses the expression of one of the com-
ponents of NF-kB (RelB), thus blocking the activation of DCs
(Dong et al, 2003) (Figure 2). The extent of this mechanism is
not known.
In summary, the data obtained to date suggest that the
activation of GC or VDR has profound inhibitory or immu-
nosuppressive/tolerogenic effects in DCs’ immunophenotype
and that these pathways are potentially amenable to ther-
apeutic exploitation. In the next section, we discuss the
function of retinoids, which show a much more complex
behaviour having both repressive and activator functions
in DCs.
Regulation of DCs by retinoids
It is well known that retinoids (derivatives of vitamin A and
ligands of RAR and RXR receptors) exert a modulatory effect
on the immune system. Vitamin A deﬁciency causes immune
dysfunction and increases the susceptibility of an individual
to infectious diseases, thus contributing to elevated child
morbidity and mortality (Underwood and Arthur, 1996).
Retinoids modulate the differentiation and functions of both
lymphocytes and DCs. There are conﬂicting results on
whether retinoids enhance or repress the immunogenicity
of DCs. It was reported that mouse splenic DCs are less
stimulatory (Bedford and Knight, 1989) on RA treatment;
however, retinoid-treated Langerhans cells have an enhanced
T-cell activation capacity (Meunier et al, 1994). Moreover, RA
promotes the differentiation and maturation of monocytes to
DC-like cells (Mohty et al, 2003) and these compounds
enhance the DNA-binding activity of NK-kB, thus promoting
the maturation of DCs (Geissmann et al, 2003) (Figure 2). It
should be noted that retinoids also provoke apoptosis
in developing DCs through RARa–RXR heterodimers
(Geissmann et al, 2003). It was also described that RA
pretreated DCs, if injected into tumours in mice, showed an
increased accumulation in draining lymph nodes. It was
concluded that the enhanced DC migration was due to
the elevated matrix metalloproteinase production and
the concurrently diminished expression of inhibitors of
metalloproteinase (Darmanin et al, 2007). Moreover, RA-
treated monocyte-derived DCs produce an elevated level of
TGFb and IL-6 and these RA-instructed DCs acquire several
attributes characteristic of mucosal DCs (Saurer et al, 2007).
Our laboratory also investigated the effects of activation of
the RARs using synthetic retinoids on human monocyte-
derived DC differentiation and found that these cells have
an enhanced iNKT cell activation capacity as a consequence
of the induction of CD1d (Szatmari et al, 2006a); moreover,
our gene expression proﬁling indicates that a large number of
genes are regulated by retinoids leading to the activation of
multiple pathways. All-trans RA is an agonist of RAR; how-
ever, an isomeric form, 9-cis-RA, can activate both RAR and
RXR (Mangelsdorf and Evans, 1995); therefore, 9-cis-RA has
pleiotropic effects and can modulate the activity of several
nuclear receptors in principle. Interestingly, 9-cis-RA exerts a
suppressive effect on human monocyte-derived DC differen-
tiation, probably through the activation of the PPARg–RXR
heterodimer (Zapata-Gonzalez et al, 2007). We also tested the
effects of a synthetic and speciﬁc activator of RXR (LG268) on
DC differentiation and obtained complex phenotypic
changes, suggesting that probably multiple nuclear receptor
heterodimers are affected (I Szatmari and L Nagy, unpub-
lished results). Exposure to retinoids has a complex pheno-
type in DCs, and as we will demonstrate in the next section,
RA has a profound effect on lymphocyte homing and activa-
tion as well.
DC as a factory of ligands for nuclear
receptors
In this review, we have systematically analysed the potential
function of the activation of various nuclear receptors in DC
development and function. It should be emphasized that
most studies used high-afﬁnity synthetic ligands for the
activation of the nuclear hormone receptors and for probing
their biological functions. Two important issues need to be
considered. One is whether the natural activators of these
receptors have similar effects on DCs. The other is whether
DCs are actively participating in the production of nuclear
hormone receptor ligands or simply get those through endo-
crine or paracrine mechanisms. It should be noted that in the
serum, a large number of compounds are present as biologi-
cally inactive precursors. However, on activation (oxidation/
hydroxylation), the inactive compounds can be converted to
the active forms. For example, vitamin D3 must be hydro-
xylated to 1,25 dihydroxy vitamin D3, which is a high-afﬁnity
ligand of VDR (Okuda et al, 1995), and vitamin A (retinol)
ﬁrst gets oxidized to retinaldehyde; thereafter, this compound
is converted to RA, which is an agonist of RARs (Duester,
2000). Similarly, cortisone is converted to cortizole, a ligand
of GR (Seckl and Walker, 2001) (Figure 3). Additionally,
hydroxylation of cholesterol at the position of 27 leads to
27-hydroxy-cholesterol, a potent activator of the LXR recep-
tors (Fu et al, 2001), and ﬁnally polyunsaturated fatty acids
are oxidized by lipoxygenases and these oxidized compounds
are relatively potent ligands of the PPARg receptor (Nagy
et al, 1998; Huang et al, 1999). The organic and cellular
localization of these steps and the enzymes that catalyse
these reactions are well characterized for some cell types.
Most of these chemical transformations occur in the liver and
Nuclear receptor signalling in dendritic cells
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found in DCs.
The most studied nuclear receptor ligand in the context of
DCs is RA, the active form of vitamin A. In a breakthrough
study, Iwata et al (2004) discovered that murine intestinal
DCs produce and release RA, and this DC-derived RA in-
structs the gut-homing tropism of T cells by the induction of
the expression of a4b7 integrin and CCR9 receptors. This
study established that a DC-derived nuclear receptor ligand is
able to reprogramme the local T cells and imprint T-cell
tropism. Interestingly, several recent publications suggest
that RA, in combination with other immunological media-
tors, modulates the differentiation of various lymphocyte
populations in the GALT. In the intestine, RA blocks the
IL-6- and TGFb-driven induction of the pro-inﬂammatory
IL-17-producing T (Th17) cells, but promotes the differentia-
tion of the tolerogenic regulatory T (Treg) cells (Mucida et al,
2007). These ﬁndings were conﬁrmed by others: intestinal
DC-produced RA enhances the TGFb-dependent conversion
of peripheral T cells to Foxp3-positive Treg cells, suggesting
that RA works as a mediator of gut/oral tolerance in vivo
(Benson et al, 2007; Coombes et al, 2007; Sun et al, 2007).
Gut-associated DCs also promote B cell gut tropism by the
upregulation of the aforementioned receptors; additionally,
they enhance the IL-6-dependent IgA secretion of B cells
(Mora et al, 2006). Collectively, these ﬁndings under-
score that DC-derived RA has a prominent function in the
regulation of gut-associated immune processes. It should be
mentioned that RA itself could induce the expression of a4b7
and CCR9 on Tcells and thus imprint gut tropism, but for the
study of the other effects of RA on lymphocytes, in most cases
DC-T cell co-cultures were used. Therefore, formally, it is
possible that RA also affects the immunophenotype of the
DCs and that these ‘reprogrammed’ DCs promote Treg devel-
opment or B-cell IgA production. Another interesting point is
to address which factors regulate RA production and which
enzymes are responsible for the unique capacity of the
intestinal DCs to produce RA. There is a remarkable selectiv-
ity of this phenotype. In vivo, only intestinal DCs of the Peyer
patches and mesenteric lymph node DCs produced RA. In
contrast, non-gut lymphoid tissue DCs are unable to generate
RA (Iwata et al, 2004). Intestinal DCs express several en-
zymes that might participate in RA synthesis, the most
important ones being the retinaldehyde dehydrogenases
(RALDHs), which catalyse the retinaldehyde oxidation to
RA (Figure 2). DCs of Peyer’s patches mostly express
RALDH1 (Aldh1a1); in contrast, mesenteric lymph node
DCs mostly express RALDH2 (Aldh1a2) (Iwata et al, 2004).
A specialized sub-population of mesenteric lymph node DCs,
CD103þ cells, promote the generation of Treg cells and these
DCs show an elevated expression of RALDH2 (Coombes et al,
2007). Interestingly, we observed that PPARg-instructed
human monocyte-derived DCs also produce RA; moreover,
RALDH2 and RDH10 (retinol dehydrogenase 10) enzymes
were upregulated in these cells (Szatmari et al, 2006a). It is
well established that RALDH2 is indispensable for embryonic
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Figure 3 The chemical structures and conversion steps of three nuclear hormone receptor ligand precursors (vitamin A, cortisone and vitamin D) to
the active compounds. Most of these chemical reactions can occur in DCs.
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recent report suggested that RDH10 might catalyse the ﬁrst
oxidation step of retinol, a critical step for embryonic RA
generation (Sandell et al, 2007). Further investigations are
needed to deﬁne what kind of mechanisms regulate RA
production in DCs and which enzyme/s is/are rate limiting
for RA synthesis. Once these issues are clariﬁed, one would
be able to deﬁne the in vivo contribution of DC-derived RA
signalling in the various immunological processes described
earlier and also beyond those.
DCs are also able to activate other vitamins: the inactive
form of vitamin D, 25-hydroxy vitamin D3, is converted to
1alpha,25 dihydroxy vitamin D3 during the ex vivo
differentiation of human DCs. This conversion is catalysed
by 25(OH)D3-1 alpha hydroxylase, which is present in
developing DCs; in addition, this enzyme is upregulated on
maturation of DCs (Fritsche et al, 2003; Hewison et al, 2003).
Consistent with these ﬁndings, the production of the VDR
ligand is claimed to negatively regulate the early differentia-
tion of monocyte-derived DCs. Of note, dermal DCs are able
to directly convert vitamin D3 to 1,25 dihydroxy vitamin D3
in the skin, and this active form of vitamin D instructed the
local Tcells to express CCR10, thus enabling them to migrate
to the epidermis (Sigmundsdottir et al, 2007). Remarkably,
these results suggested that similar to RA, which elicits
gut-homing speciﬁcity of T cells, the active form of vitamin
D imprints skin-homing speciﬁcity of T cells (Figure 4).
Human monocyte-derived DCs are also able to convert the
inactive cortisone to the high-afﬁnity GR ligand, cortisole as a
result of the upregulation of 11beta hydroxysteroid reductase.
In addition, DC differentiation is inhibited by the administra-
tion of physiological concentration of cortisone, suggesting
that this pathway enhances the GC-dependent negative mod-
ulation of DC development (Freeman et al, 2005). Finally, as
far as the PPARg ligand is concerned, we observed that during
monocyte-derived DC development the bona ﬁde PPARg
targeting the FABP4/aP2 gene is upregulated, especially
when we culture the cells in human serum instead of FBS
(Szatmari et al, 2004). We extended this ﬁnding and observed
that most of these genes whose expression was upregulated
on synthetic PPARg ligand treatment also showed an elevated
expression if DCs were cultured in human serum-containing
medium (Szatmari et al, 2007). These results suggested that
in the presence of human serum, the PPARg ligands are
generated/accumulated in DCs. Further experiments are
warranted to identify the PPARg activators. Indeed, a recent
paper suggested that lysophosphatidic acid and cardiolipin
are abundant components of the human serum and that these
lipid species might contribute to the activation of PPARg
(Leslie et al, 2008).
These results underscore the notion that, remarkably, DCs
are actively participating in the production of several ligands
of nuclear receptors. The production of ligands appears to be
tightly controlled, however. Moreover, some of these ligands
are likely to be released and are able to locally modulate the
function of other immune cell types.
Concluding remarks: DCs as potential
therapeutic targets
The functional characterization of DC is an intensively in-
vestigated area in immunology. DCs are indispensable for the
initiation of primary immune response, but now it is well
established that these cells are able to orchestrate the entire
immune response, including the regulation of peripheral
immune tolerance. Therefore, it is of importance to identify
and characterize the regulatory processes underpinning these
changes. It is becoming increasingly evident that members of
the nuclear hormone receptor superfamily are involved
in the regulation of DC biology. This group of transcription
factors also represents a gateway to manipulating DCs for
therapeutic use. In clinical practice, tumour antigen-loaded
DCs are intensively investigated tools to elicit
antitumour immune response. Ex vivo differentiated DCs
may be loaded with tumour antigens and injected back to
patients, or they can be used for ex vivo expansion of
antitumour lymphocytes. Improving anticancer immu-
notherapies appear to largely depend on how DC immuno-
genicity, survival and migration are regulated, and thus it is
very important to ﬁnd ways to modulate antigen presenting,
migratory capacity and viability of DCs (Nencioni et al,
2008). There are several ways to manipulate DCs ex vivo;
administration of cytokine cocktails or other signal molecules
can modify the DC function and activation state. As we have
Retinoic acid
Foxp3+ Treg development
Gut-homing tropism 
of T cells
IgA production of B cells
Skin-homing tropism 
of T cells 1,25(OH)2 vitamin D3
Inhibition of Th17 development
CCR9 α4β7
CCR10
Figure 4 DC-produced nuclear receptor ligands modulate T-cell development and homing. Intestinal DCs produce the active form of vitamin A
(retinoic acid). In contrast, skin DCs could secrete the active form of vitamin D (1,25 dihydroxy vitamin D3). Retinoic acid (RA) imprints gut-
homing tropism of lymphocytes by inducing a4b7 integrin and CCR9 receptor; in addition, RA contributes to B-cell IgA production; moreover,
this compound promotes FoxP3þ Treg cell differentiation but blocks Th17 T-cell development. 1,25 Dihydroxy vitamin D3 primes skin-homing
tropism of T cells by inducing CCR10.
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nuclear hormone receptors can also modulate DC functions.
In the future, it will be important to explore and exploit the
beneﬁt of ligand treatment to modulate DC immunogenicity
in vivo. An inverse relationship should also be considered.
The metabolic state of the patient might affect his/her
immune responses. DCs express several lipid sensor nuclear
hormone receptors (i.e. PPARg LXRa). Thus, in patients with
an altered lipid proﬁle, these receptors might be overactivated
and this can adversely modify the immune phenotype of their
DCs. As an example, we have described that serum lipopro-
teins skewed DC development towards a CD1a  DC pheno-
type, which has a distinct cytokine and chemokine
production proﬁle (Gogolak et al, 2007).
Until now, most of the studies on nuclear receptors used ex
vivo DC models and only a few reports investigated tissue-
speciﬁc nuclear receptor knockout models (Grifﬁn and
Kumar, 2003; Klotz et al, 2007). In the future, it will be of
great importance to generate DC-speciﬁc nuclear receptor
deletion models. These models will almost certainly prove
to be helpful to deﬁne the receptor speciﬁcity of the effects of
receptor agonists. In addition, these systems will help to
deﬁne the in vivo function of these receptors in DCs. The in
vivo approaches might also clarify some of the controversies
that still exist in the ﬁeld. However, as we have emphasized
concerning human immunotherapy, ex vivo DC models are
also used. Thus, it is important to characterize the in vitro
effects of ligands of nuclear hormone receptors, not in small
part, because there are major differences between mice and
humans regarding DC functions, and murine models might
not always be predictive of human responses. DCs are a very
heterogeneous cell population (Villadangos and Schnorrer,
2007), and until now most data were derived from human
monocyte-derived DCs. In the future, it would also be im-
portant to deﬁne the function of nuclear receptors/ligands on
the various subtypes of DCs and DC precursors. And, ﬁnally,
activators of nuclear receptors are widely used in clinical
practice, for example, ligands of the PPARg (rosiglitazone and
pioglitazone) are applied to treat type II diabetes (Willson
et al, 2001); in addition, GCs are frequently used as immu-
nosuppressive agents. Deﬁning the exact functions of these
activators in various immune cell types could help in exploit-
ing their potential for therapeutic intervention against various
immunological diseases.
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